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ComorbidityIn healthcare organizational settings, the design of a clinical pathway (CP) is challenging since patients
following a particular pathway may have not only one single first-diagnosis but also several typical
comorbidities, and thus it requires different disciplines involved to put together their partial knowledge
about the overall pathway. Although many data mining techniques have been proposed to discover latent
treatment information for CP analysis and reconstruction from a large volume of clinical data, they are
specific to extract nontrivial information about the therapy and treatment of the first-diagnosis. The
influence of comorbidities on adopting essential treatments is crucial for a pathway but has seldom been
explored. This study proposes to extract latent treatment patterns that characterize essential treatments
for both first-diagnosis and typical comorbidities from the execution data of a pathway. In particular, we
propose a generative statistical model to extract underlying treatment patterns, unveil the latent associ-
ations between diagnosis labels (including both first-diagnosis and comorbidities) and treatments, and
compute the contribution of comorbidities in these patterns. The proposed model extends latent
Dirichlet allocation with an additional layer for diagnosis modeling. It first generates a set of latent treat-
ment patterns from diagnosis labels, followed by sampling treatments from each pattern. We verify the
effectiveness of the proposed model on a real clinical dataset containing 12,120 patient traces, which
pertain to the unstable angina CP. Three treatment patterns are discovered from data, indicating latent
correlations between comorbidities and treatments in the pathway. In addition, a possible medical appli-
cation in terms of treatment recommendation is provided to illustrate the potential of the proposed
model. Experimental results indicate that our approach can discover not only meaningful latent treat-
ment patterns exhibiting comorbidity focus, but also implicit changes of treatments of first-diagnosis
due to the incorporation of typical comorbidities potentially.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Although overhyped, and sharply criticized repeatedly over the
past 20 years, clinical pathways (CPs) have remained on the agenda
of many healthcare organizations [1,2]. The simple reason is that
CPs, as defined set of therapy and treatment activities that repre-
sent the steps required to achieve a specific treatment objective
for a particular disease, are recognized as one of the most useful
tools to increase the quality of care services in an unfavorable eco-
nomic scenario and under the financial pressure by governments
[1–5].Since 2010, Chinese government has published over 200 CP
specifications, which are required to be implemented in more than
one hundred pilot hospitals [6,7]. Each CP specification is a stan-
dardized/normalized treatment guideline of a particular disease,
and is assumed to provide actionable knowledge to schedule the
best practice for individual patients in their hospitalizations [5].
However, actual treatment activities are extremely complex, with
numerous variations across various stages in the execution of
CPs, and they often bear no relation to the ideal as envisaged by
the designers of CPs [8–10]. In particular, since a CP specification
is generally designed for a single first-diagnosis, the treatments
on the typical comorbidities are easily neglected in the pathway
design phrase [11]. For example, the unstable angina CP
describes the guideline-conform and consented management of
unstable angina patients with ST-segment elevation infarct,
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angina [12]. However, treatment interventions for typical comor-
bidities of unstable angina, e.g., Diabetes, Hypertensions, etc., are
not well explained in the pathway specification. Note that there
are more than 70 comorbidities of unstable angina patients, and
many comorbidities (e.g., Kidney deficiency) afflict the unstable
angina pathway seriously, and incur deviations from the prede-
fined CP specification [13]. According to a survey [39] we have per-
formed at the Cardiology department of Chinese PLA general
hospital, the compliance rate of the unstable angina pathway is
about 7.2%, which is significantly below the well-recognized
threshold value (i.e., 40%,) for the meaningful use of CPs [14]. Clin-
icians indicate that the main reason for this is that the predesigned
unstable angina pathway specification lacks the support for the
treatments of comorbidities and complications [1,15–17]. As a
result, patient care-flow may not go well towards the expected
direction, and there are deviations from the pre-defined CP speci-
fications [18,38].
To design feasible CPs, it is increasingly important to study
actual treatments between a particular first-diagnosis and its com-
mon comorbidities to extract nontrivial knowledge in CPs, and to
help clinical analysts to redesign/refine CPs. Recently, the fast
development of healthcare information systems produces a large
volume of electronic clinical data to record actual execution situa-
tions in CPs and thus provides a comprehensive source for explora-
tory analysis and statistics to benefit many real applications for CP
analysis and redesign [19,20]. In fact, many data mining and
machine learning techniques have been proposed to utilize these
execution data to extract useful information for CP analysis and
redesign [20,21]. This, also called process mining, has been recog-
nized as an objective way of analyzing CPs as it is not biased by
perceptions or normative behaviors [4,22]. In particular, it can pro-
vide insight about what is actually happening, and ultimately the
knowledge extracted from clinical data can be used for effective
improvement of clinical pathways and of their supporting systems
[22].
However, most existing process mining approaches analyze
treatment behaviors from the first-diagnosis perspective, and sel-
dom studied the influence of typical comorbidities on treatment
adoption in CPs. Note that, in clinical practice, the different aspects
of treatment information are highly correlated, and clinicians are
very interested in the latent associations between comorbidities
and treatments. In particular, they wonder what kind of treatment
activities should be given to patients who have some specific
comorbidities. And how will the different comorbidities influence
individual patients’ treatment processes? Etc.
A straightforward method to address this problem is to manu-
ally build a dictionary of treatment events for each typical comor-
bidity. But building such a treatment dictionary is not only labor
consuming, but also unable to quantize the connection strengths
between treatments and comorbidities. As an alternative, discrim-
inative methods, such as Decision Tree, and SVM, can provide a
principled way to estimate comorbidity-treatment associations
using their concurrence counts in a clinical dataset [20]. However,
since such approaches treat each treatment event individually,
most relevant treatments extracted for each comorbidity are
usually mixed with background and the first-diagnosis-oriented
treatment events. Moreover, it is more sensible to associate
comorbidities with a specific comorbidity-incorporated treatment
pattern instead of only a single treatment event.
In this study, we explore the problem of comorbidity-
incorporated treatment pattern discovery using the execution data
of CPs. In particular, we proposed a generative statistical model
named Diagnosis Treatment Model (DTM) to mine underlying
treatment patterns from data. The proposed DTM, as an extension
of Latent Dirichlet Allocation (LDA) [23], can be applied to the taskof comorbidity-incorporated treatment pattern mining, and allows
us to infer the contributions of comorbidities on the treatments
adoption in CPs [19,24,25]. It first generates a treatment pattern
from a multinomial distribution conditioned on diagnosis labels,
and then generates treatment activities and their occurring time
stamps from other multinomial distributions based on latent treat-
ment patterns. As a complete generative model, the proposed
model is capable of distinguishing between different therapy pur-
poses of the same treatment activity, and discovering meaningful
treatment patterns resulted from typical comorbidities, since the
patient care-flow with specific comorbidities is characterized by
its latent treatment patterns rather than individual treatment
activities. We test the proposed model on a real clinical dataset
gathered from Chinese PLA General Hospital. The remainder of this
paper is organized as follows: Section 2 discusses related work;
Section 3 presents the proposed model for comorbidity-
incorporated latent treatment pattern mining. The dataset, exper-
imental results and discussions are illustrated in Section 4. Finally,
we draw conclusions in Section 5.2. Related work
The most related direction to our work is healthcare process
mining/analysis [22,26,27]. Process mining, as a valuable set of
techniques, has been widely studied in business process manage-
ment domain [26]. It uses process event logs to record business
process execution information, to mine the actual behaviors in
business processes, and discover business process patterns [22].
Based on process event logs, with its logic and reasoning ability,
process mining guarantees integrity, objectivity and universality
of the discovered process patterns [22].
Process mining techniques have gained gradual attentions in
the healthcare domain, and has already been attempted by some
researchers [22,28–32,36,37]. Work that is closely related to ours
is presented in 2013, in which Lakshmanan et al., presented a
hybrid approach for mining CPs correlated with patient outcomes
that involves a combination of clustering, process mining and fre-
quent pattern mining [33]. Their work takes clinical outcomes into
account in mining treatment processes. In particular, they describe
an algorithm to mine the structure of a clinical pathway using fre-
quent pattern mining, and rank the frequent patterns according to
the degree of their correlation with a patient outcome. In this
sense, an individual clinical pathwaymined from real patient event
data in the form of a frequent pattern may contain a small subset
of the overall possible set of events that could be applied to treat a
particular disease. As valuable as their approach, the comorbidity-
oriented issues, such as the correlations between the mined
patterns and comorbidities, and the implicit changes of treatments
of the first-diagnosis due to the incorporation of typical comorbidi-
ties, were not addressed in their work.
The use of traditional process mining techniques though suc-
cessful in discovering latent treatment knowledge can prove inad-
equate in CP analysis [20–22]. Note that the complexity, dynamic,
and ad hoc natures of CPs are far higher than that of common busi-
ness processes [22]. Using the traditional process mining tech-
niques, it may generate incomprehensible and even spaghetti-
like treatment patterns [21,24]. Note that CPs deal with a variety
of medical problems. Therefore, it can be assumed that a patient
trace is actually guided by multiple underlying treatment patterns
[19,25]. For example, a patient who follows the unstable angina CP
may also be performed specific activities for his/her diabetes treat-
ments. To this end, it is advocated to develop new process mining
techniques facilitating CP analysis. In our previous work, we devel-
oped a generative topic model to derive latent treatment patterns
hidden in clinical data [19]. Discovered treatment patterns, as
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patients in most time of their treatment journeys, form the back-
bone of CPs, and can be exploited to help physicians better under-
stand their specialty and learn from previous experiences for CP
analysis and redesign [20].
Despite the success of previous work on healthcare process
mining and analysis, existing approaches usually discover underly-
ing treatment patterns for the therapy of first-diagnosis, such that
the influence of typical comorbidities in CPs seems to be over-
looked in the literature. This also prevents clinical analysts from
further understanding the contributions of typical comorbidities
on the therapy and treatment in CPs, because the comorbidities
may not only lead to newly and unexpected comorbidity-
oriented treatments but also change the original treatment behav-
iors w.r.t the first-diagnosis in CPs. In fact, it is no wonder that
patients with a specific type of comorbidity may have a different
treatment strategy other than the patients without that comorbid-
ity in clinical practice. In this sense, comorbidity-incorporated
treatment pattern mining is crucial for CP analysis and redesign.
3. Methodology
In this section, we present a generative statistical model for
comorbidity-incorporated treatment pattern mining, namely, the
Diagnosis Treatment Model (DTM). The problem is firstly defined.
Then, we present our model in detail.
3.1. Problem definition
In this study, our goal is to extract latent associations between
comorbidities and treatments about a particular CP from theA0:Admission
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Fig. 1. A clinical eveexecution data. These execution data are also called clinical event
log, which conceals an untapped reservoir of knowledge about the
way of specific therapy and treatment activities being performed
on particular patients in their hospitalizations. Formally, let A be
the treatment activity domain, and T the time domain, and C the
disease type domain. We assume that a clinical event log L consists
of jLj patient traces. Each patient trace r (r 2 L) includes both a set
of diagnosis labels Cr#C, and a finite non-empty set of treatment
events < e1; e2; . . . ; ejrj

performed on a particular patient during
his/her hospitalization. A treatment event ei is represented as
ei ¼ ðai; tiÞ, where ai is the activity type of ei (ai 2 A), and ti is the
occurring time of ei (ti 2 T). For convenience, let ei  a and ei  t be
the treatment activity type and the occurring time stamp of ei,
respectively. A treatment event is a performed treatment activity
at a particular time stamp.
For example, Fig. 1 shows a clinical event log example consist-
ing of 5 patient traces. The predefined disease label domain con-
tains one first-diagnosis (‘‘Unstable angina”), and seven typical
comorbidities (i.e., ‘‘Ulcer”, ‘‘Anterior myocardial infraction”, ‘‘One
degree atrioventricular block”, ‘‘Carotid atherosclerosis”, ‘‘Anemia”,
‘‘Diabetes”, and ‘‘Hypertension”). Thus, jLj and jCj respectively equal
to 5 and 7. Each patient trace is a set of clinical events and has been
assigned particular disease labels: Cr1 = {‘‘Unstable angina”,
‘‘Ulcer”} and Cr2 = {‘‘Unstable angina”, ‘‘Anterior myocardial infrac-
tion”}, etc. Our objective is to accurately model the associations
between diagnosis labels and treatment events, and improve the
performance of latent treatment pattern discovery by taking the
first-diagnosis and typical comorbidities into account. Table 1
summarizes the notations of these frequently-used variables.
In our previous work, we have presented a generative statistic
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Table 1
Notations of frequently-used variables in this paper.
Symbol Description
L Clinical event log
C Diagnosis labels in L
r Patient trace in L
Nr Number of treatment events in patient trace r
Cr Set of diagnosis labels in patient trace r
Z Universe of treatment patterns
A The domain of treatment activity types in L
T The domain of occurring time stamps of treatment events in L
er;i The ith treatment event in patient trace r, i.e., er;i ¼ ha; ti, where
a 2 A, and t 2 T
a Dirichlet prior of h
b Dirichlet prior of /
c Dirichlet prior of u
h Multinomial distribution of treatment patterns given the diagnosis
labels in L
/ Multinomial distribution of treatment activity types to treatment
patterns in L
u Multinomial distribution of occurring time stamps of treatment
activities to treatment patterns in L
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the notations hr, /, and u are used to present the patient trace-
treatment pattern, treatment pattern-activity, and treatment
pattern-activity-time stamp distributions, respectively. The hyper-
parameters are denoted by a, b, and c. In particular, the hyperpa-
rameter a is a Dirichlet prior of h, which can be interpreted as
the prior observation counts for the number of times the topic
was sampled from patient trace before any treatment event is
observed. The hyperparameter b is a Dirichlet prior of /, which
can be treated as the prior observation counts for the number of
times treatment events with particular activity types were sam-
pled from treatment pattern before any actual clinical event has
been observed. The hyperparameter c is a Dirichlet prior of u,
which can be interpreted as the prior observation counts for the
number of occurring time stamps of clinical events with particularFig. 2. (A) Clinical Pathway Model (CPM) [24], and (B) Diagnosis Treatment Model
(DTM).activity types were sampled from treatment patterns before any
treatment event has been observed. While CPM utilizes the
contextual information within the patient traces, it fails to utilize
the diagnosis information to guide the treatment pattern
generation.
This work can be seen as building on earlier ideas from our pre-
vious work in probabilistic modeling for latent treatment pattern
mining in CPs. We describe in the next subsection the DTM. As a
complete generative model, the proposed DTM allows us to associ-
ate each treatment pattern with both treatment events and diag-
nosis labels jointly, and to infer the influence of particular
comorbidities on the therapy and treatment of patients in CPs.
3.2. Diagnosis-treatment model
CPM discloses the underlying treatment patterns in patient
traces of a clinical event log. However, CPM does not identify
comorbidities of a patient trace nor the association of comorbidi-
ties to each treatment pattern of a patient trace. To this end, we
propose the Diagnosis Treatment model, an extension of CPM, that
models the treatment events of a patient trace and the contribu-
tions of both first-diagnosis and typical comorbidities. As illus-
trated in Fig. 2(B), the proposed DTM can also associate
treatment events and diagnosis labels jointly, and infer the contri-
butions of comorbidities on treatment behaviors of patient traces.
The generative process for DTM is described as follows:
1. For each diagnosis label c, choose jCj multinomials
hc  DirðaÞ.
2. For each patient trace r in the event log L.
(1) For each clinical event er;i in r.
(a) Choose a diagnosis label ci  UniformðcrÞ.
(b) Choose a treatment pattern zi  MultinomialðhcÞ.
(c) Choose a treatment activity type
er;i  a  Multinomialð/zÞ.
(d) Choose an occurring time stamp
er;i  t  Multinomialðuz;aÞ.
The procedure begins by choosing a diagnosis label c, randomly at
uniform, form the set of diagnosis labels cr of r. Afterward, the
multinomial distribution hc , from the Dirichlet distribution a, is
picked, and this distribution determines which treatment patterns
are most likely to be assigned to the diagnosis label c. Next, a single
treatment pattern z is sampled for each treatment event ei in r,
from the multinomial distribution hc associated with the diagnosis
label c for that event. Finally, the event type ei  a and the occurring
time stamp eio  t of ei are generated based on the multinomial dis-
tribution /z, and uz;a, respectively, where /z is generated from the
Dirichlet distribution b for each treatment pattern z, and uz;a is gen-
erated from the Dirichlet distribution c form each treatment pattern
z and each treatment activity type a.
The joint probability of all the random variables for a clinical
event log is as follows:
Pðe; c; z; h;/;ujC;a;b; cÞ ¼ PðhjaÞPð/jbÞPðujcÞPðzja; cÞPðcjCÞ
Pðe  ajz;/ÞPðe  tjz; e  a;uÞ: ð1Þ
Since it is intractable to perform an exact inference, we use the
approximate inference based on Gibbs sampling to estimate the
parameters [34]. Specifically, for each treatment event, we esti-
mate the posterior distribution on diagnosis label c and treatment
pattern z based on the following conditional probabilities, which
can be derived by marginalizing the above joint probabilities in
Eq. (1).
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z2Znci ;z þ jZja
 nz;ei a þ bP
a02Anz;ei a0 þ jAjb
 nz;ei a;ei t þ cP
t02Tnz;ei a;ei t0 þ jTjc
; ð2Þ
where zi and ci are the candidate treatment pattern and diagnosis
label that ei is assigned to, zi refers to the pattern assignments of
all other treatment events, ci refers to the diagnosis label assign-
ments of all other treatment events, nc;z is the number of instances
of treatment pattern z that has been assigned to diagnosis label c,
nz;ea is the number of instances of treatment activity type e  a that
has been assigned to treatment pattern z, and nz;ea;et is the number
of instances of the occurring time stamp e  t of the activity type e  a
that has been assigned to treatment pattern z. The suffix i means
the number that does not include the current assignment of treat-
ment event ei.
With the sampled treatment patterns available, it is easy to esti-
mate the probability of treatment pattern z conditioned on diagno-
sis label c, the probability of activity type a conditioned on
treatment pattern z, and the probability of occurring time stamp
t conditioned on treatment pattern z and clinical activity type a,
by the following equations:
hc;z ¼ nc;z þ aP
z02Znc;z0 þ jZja
; ð3Þ
/z;a ¼
nz;a þ bP
a02Anz;a0 þ jAjb
; ð4Þ
uz;a;t ¼
nz;a;t þ cP
t02Tnz;a;t0 þ jTjc
; ð5Þ
With all the parameters derived above, the proposed DTM can
be utilized for various applications. For example, associations
between diagnosis labels (including both first-diagnosis and
comorbidities) and treatment behaviors can be revealed using
the estimated treatment pattern proportions. It can assist to esti-
mate the probability of a treatment activity a and its occurring
time stamps t (a.k.a a treatment event) given a set of comorbidities
of a specific particular patient in his/her treatment journey:
Pða; tjCrÞ ¼
X
c2Cr
Pða; tjcÞ ¼
X
c2Cr
X
z2Z
Pðtja; zÞPðajzÞPðzjcÞ
¼
X
c2Cr
X
z2Z
uz;a;t/z;ahc;z: ð6Þ
The worst case time complexity of each iteration of the Gibbs
sampler is OðZATCmaxÞ, where Z is the number of treatment pat-
terns, A is the number of activity types, T is the number of occur-
ring time stamps, and Cmax is the maximum number of diagnosis
labels that can be associated with a single patient case. As the com-
plexity is linear in AT, Gibbs sampling can be efficiently carried out
on large data sets.
4. Experiments
In this section, we firstly evaluate the performance of the
proposed model on comorbidity-incorporated treatment patternTable 2
The details of the experimental event log.
Number of patient
traces
Number of
events
Number of activity
types
Number of comorbidit
types
12,120 706,348 617 76mining in a quantificational manner. The experiments are, firstly,
designed to analyze the influence of latent treatment pattern num-
bers. We then conduct a qualitative investigation on the generated
treatment patterns using the proposed models, to study the effect
of the proposed model on mining latent associations between
comorbidities and treatments.4.1. Experiment design
To test the effectiveness of the proposed model, we have col-
lected an experimental log from the cardiology department of Chi-
nese PLA General Hospital. The CP of unstable angina is selected in
this case study. Unstable angina is a kind of chest discomfort or
pain that occurs in a continuous and unpredictable way. The cause
of angina is commonly the poor blood flow in coronary vessels
caused by atherosclerosis and the lack of oxygen supply to the
myocardium. While the risk of unstable angina is high, the popula-
tion of unstable angina is huge, especially for aged people and
those with associated disease such as hypertension and diabetes
[12,13]. Thus, the discovery of latent associations between comor-
bidities and treatments and the underlying treatment patterns in
the unstable angina CP will be of significant value and interest.
In this case study, 12,120 patient traces following the unstable
angina CP were selected from the cardiology department to
demonstrate the ability of the proposed method to discover
comorbidity-incorporated treatment patterns. Each patient trace
in the experimental log consists of one or a set of diagnosis types
including the first diagnosis ‘‘Unstable angina” and a set of comor-
bidities, e.g., Hypertension, Diabetes, etc. Table 2 summarizes the
statistics of the collected event log.
In contrast to the clinical datasets typically utilized in research,
the event logs collected from real clinical settings contain not only
tens of thousands of treatment events, but also hundreds of diag-
nosis labels indicating various comorbidities of patients following
particular pathways. In addition, the frequencies of diagnosis label
in clinical event logs tend to have highly skewed frequency-
distributions with power-law statistics. Fig. 3 illustrates this point
for a real clinical event log pertaining to the unstable angina CP. It
contains 80 unique comorbidities, and the total number of diagno-
sis labels is plotted as a function of label-frequency on a log–log
scale (i.e., more precisely, number of unique labels [y-axis] that
have been assigned to M patient traces in the event log is plotted
as a function of M [x-axis]). Of note is the power-law like distribu-
tion of label frequencies for the experimental log, in which the vast
majority of labels are associated with very few patient traces, and
there are relatively few labels that are assigned to a large number
of patient traces. For example, roughly 55 diagnosis labels are only
assigned to less than 10 patient traces (<0.1% of patient traces in
the experimental log), and the mean diagnosis label-frequencies
is 2.5.
To evaluate the proposed DTM, we also developed a Naïve Bayes
based model to derive latent treatment patterns from the experi-
mental log. Fig. 4 illustrates the generation process of the Naïve
Bayes based model generates each clinical event ei in three sam-
pling steps, i.e., sample a diagnosis label ci according to the uni-
form distribution from cr, sample the activity type ei  a of ei
given the diagnosis label under the conditional probability
Pðei  ajciÞ, and sample the occurring time stamp ei  t of ei giveny Minimum length of stay
(day)
Maximum length of stay
(day)
Average length of stay
(day)
1 94 9.9
Fig. 3. The number of training patient traces for each unique diagnosis label in the experimental log.
Nσ
L
a
cσ
t
c
Fig. 4. A Naïve Bayes method for comorbidity-incorporated treatment pattern
mining.
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conditional probability Pðei  tjci; ei  aÞ. Note that the model param-
eters can be learned by maximum-likelihood estimation. In partic-
ular, the conditional probability of a treatment activity type a given
a diagnosis label c, and the conditional probability of an occurring
time stamp t given a diagnosis label c and a treatment activity type
a, can be estimated as follows:PðajcÞ ¼ na;cP
a02Ana0 ;c
; ð7Þ
Pðtjc; aÞ ¼ na;t;cP
t02Tna;t0 ;c
; ð8Þ
where na;c is the co-occurrence count between treatment activity a
and diagnosis label c for all patient traces in the experimental log,
and na;t;c is the co-occurrence count between treatment activity a,
its occurring time stamp t and diagnosis label c for all patient traces
in the experimental log, respectively.
4.2. Treatment pattern number selection
The number of treatment patterns Z indicates how many latent
aspects of patient traces can be derived, which may influence the
performance of the proposed model. Note that the performance
of the Naïve Bayes based model does not change with a different
number of treatment patterns since it does not consider the latent
aspects in patient traces. In this subsection, we focus on selecting
the number of latent treatment patterns based on topic modeling
performance, which is measured by conditional perplexity. Per-
plexity is a standard measure to compare probability models. In
this study, we calculate the perplexity on generating treatment
event e from diagnosis label c as follows:
PerpðLÞ ¼ exp 
P
r2L
P
ei2r ln PðeijcrÞP
r2Ljrj
( )
; ð9Þ
where PðeijcrÞ is the probability of generating a particular clinical
event ei conditioned on a set of diagnosis labels cr, which can be
estimated as
PðeijcrÞ¼
X
z2Z
Pðei ajzÞPðei  tjei a;zÞPðzjcrÞ/
X
c2cr
X
z2Z
/z;ei auz;ei a;ei thc;z
ð10Þ
Fig. 5. Perplexity over number of latent treatment patterns with iteration number of 1000.
Fig. 6. Perplexity over number of Gibbs sampling iterations with treatment pattern number of 3.
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PðeijcrÞ ¼
X
c2cr
Pðei  ajcÞPðei  tjei  a; cÞ; ð11Þ
where Pðei  ajcÞ and Pðei  tjei  a; cÞ can be calculated using Eqs. (7)
and (8).
Fig. 5 shows the perplexity curves of both DTM and Naïve Bayes
based model with a growing number of latent treatment pattern
numbers. Note that, because the Naïve Bayes based model does
not consider latent treatment patterns, its perplexity does not
change with a growing number of treatment patterns. As shown
in Fig. 5, the proposed DTM converges to its asymptote within a
relative small number of treatment patterns, and becomes less
than the baseline when the pattern number is more than 3. The
lower the perplexity, the better the derived model fits with the col-
lected data-set. In general, the model perplexity decreases with thenumber of pattern increases. On the other hand, if the number of
patterns is larger, the derived model may over-explain the data-
set, and it requires more sampling computation and storage as well
[35]. Thus, it needs to choose a balance between simplicity of the
model and the degree of fitness. To this end, we examined the dis-
covered patterns by DTMwith different value of Z by a simple way:
i.e., if the reducing ratio of perplexity is less than a particular
threshold value e, we do not select a larger Z. In this study, we
set e to be 3%, and empirically choose the number of patterns
Z = 3 for the experimental data set, where the perplexity seems
to decrease rapidly and appear to settle down.
Furthermore, we investigate the impact of the number of itera-
tions of Gibbs sampling on the experimental results. Fig. 6 shows
the perplexity curves of both DTMwith 3 latent treatment patterns
and the Naïve Bayes basedmodel against the number of Gibbs sam-
pling iterations. As depicted in Fig. 6, the proposed DTM converges
Fig. 7. The generated comorbidity-incorporated treatment Pattern-1. (A) Top 8 most related comorbidities and their probabilities, (B) top 40 most related treatment activities
and their probabilities, and (C) the probabilities of occurring time stamps of top 40 most related treatment activities.
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Fig. 8. The generated comorbidity-incorporated treatment Pattern-2. (A) Top 8 most related comorbidities and their probabilities, (B) top 40 most related treatment activities
and their probabilities, and (C) the probabilities of occurring time stamps of top 40 most related treatment activities.
Z. Huang et al. / Journal of Biomedical Informatics 59 (2016) 227–239 235in less than 200 iterations. After its convergence, the perplexity of
DTM is noticeably less than that of the Naïve Bayes based model.
Based on above observations, we choose 3 latent treatment
patterns and 200 iterations as the default setting in thefollowing experiments. For the other hyperparameters a, b
and c, they are set to symmetric Dirichlet priors with values of
50/Z, 0.1, and 0.1, respectively, which are similar to the previous
work [24].
Fig. 9. The generated comorbidity-incorporated treatment Pattern-3. (A) Top 8 most related comorbidities and their probabilities, (B) top 40 most related treatment activities
and their probabilities, and (C) the probabilities of occurring time stamps of top 40 most related treatment activities.
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As stated earlier, the proposed DTM can jointly model the latent
treatment patterns and patient’s comorbidities. Fig. 7 offers a dee-
per understanding on treatment pattern discovery by showing the
top 8 comorbidities (ranked by hc;z) and top 50 treatment activities(ranked by /z;a) and their occurring time stamps for the discovered
patterns. Clearly, therefore, different treatment behaviors exist for
patients with different comorbidities. The samples indicate that
the proposed DTM can discover meaningful latent treatment pat-
terns with trigger first-diagnosis and typical comorbidities, where
both explicit and implicit treatment events are identified. Pattern 1
Fig. 10. Comorbidity distribution over treatment patterns.
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onary angiography” and ‘‘Stenting”, etc.) for unstable angina. There
is little variation occurred and common treatment activities are
carried out smoothly. The activity ‘‘Discharge” occurs in the 3rd
to 12th day after ‘‘Admission”, indicating that patients who follow
this pattern have shorter LOS (less than 12 days) than others, and
almost all physical examinations (e.g., ‘‘Ultrasonography”, ‘‘X-ray”,
‘‘CT Examination”, etc.) are performed on the first day after ‘‘Admis-
sion”. It indicates that Pattern 1 is a background treatment pattern
for unstable angina CP.
In comparison with Pattern 1, Pattern 2 shown in Fig. 8 contains
typical conservative treatments of unstable angina, e.g., ‘‘Anti-ang-
ina therapy”, ‘‘Antiplatelet therapy”, etc. As shown in Fig. 8, Pattern 2
also contains a typical treatment, i.e., ‘‘b-adrenergic receptor block-
ers”, which is not included in the representative treatments of Pat-
tern 1. Note that this is a particular treatment activity for a typical
comorbidity ‘‘Sick sinus syndrome” of unstable angina. Other expli-
cit interventions for several typical types of comorbidities of unsta-
ble angina, e.g., ‘‘Hyperlipidemia”, ‘‘Hypertension”, ‘‘Diabetes”, etc.,
can also be found in Pattern 2, such as ‘‘Lipid regulation” and
‘‘Anti-diabetic therapy”. In general, patients who follow treatment
Pattern 2 is larger than two weeks.
Moreover, it is interesting to see that ‘‘Pattern 3”, as shown in
Fig. 9, has captured typical treatments of unstable angina patients
who have more complex conditions than others such that many
serious comorbidities can be found in this pattern, e.g., ‘‘Renal
insufficiency”, ‘‘Tumor”, ‘‘Cardiac insufficiency”, etc. In general,
patients who follow Pattern 3 prefer to a conservative treatment
strategy, and essential treatments for the typical comorbidities
are disclosed in Pattern 3, such as ‘‘Diuretics” for ‘‘Cardiac insuffi-
ciency” and ‘‘Tumor markers checks” for ‘‘Tumor”.
Furthermore, the proposed DTM can discover the changes of
treatment behaviors of the first diagnosis due to the occurrence
of specific comorbidities. For example, Pattern 1 includes the
typical treatment intervention ‘‘Coronary angiography” for the
first-diagnosis unstable angina, on the other side, Pattern 3 lists
treatment interventions for unstable angina patients with the
comorbidity ‘‘Renal insufficiency”, in which ‘‘Coronary angiography”
is not included. It clearly indicates the influence of the typical
comorbidity ‘‘Renal insufficiency” on the treatments of unstable
angina. It indicates that the generated pattern can reflect not only
explicit treatment behaviors w.r.t the therapy of typical comorbidi-ties of the first diagnosis, but also implicit changes of treatments of
the first-diagnosis due to the incorporation of typical comorbidities
potentially. Although the baseline Naïve Bayes based model can
also associate diagnosis labels and treatment events, the influence
of comorbidities on the therapy and treatment of the first-
diagnosis cannot be disclosed like the ones shown in Fig. 9.
As we illustrated above, the Naïve Bayes based model cannot
utilize the co-occurrence information of treatment activities
within particular patient traces and thus cannot distinguish the
background treatment inventions for the first-diagnosis from the
specific treatment interventions for particular comorbidities. On
the other side, traditional probabilistic statistical models (e.g.,
LDA, CPM, etc.) can only discover hidden treatment patterns
underlying clinical event log and cannot derive the correlations
between comorbidities and treatment interventions. Our DTM uti-
lizes the complementary advantages of both approaches. In partic-
ular, the proposed DTM has the ability to uncover latent treatment
patterns that exhibit strong comorbidity-focus. Fig. 10 shows the
distribution of top 10 comorbidities (ranked by frequency) over
the three discovered treatment patterns. It is easy to see that there
are no single-comorbidity-focused treatment patterns and all three
discovered patterns are multi-comorbidity-focused, which share a
variety of comorbidities at the same time. In addition, Fig. 10
shows some correlations between comorbidities. For example, Pat-
tern 1 is dominated by the comorbidities ‘‘Atherosclerosis” and
‘‘Coronary heart disease”, which also has similar distributions over
all three discovered patterns. In addition, similar trends can be
found for comorbidities ‘‘Cardiac insufficiency” and ‘‘Renal insuffi-
ciency”. In clinical practice, patients who have ‘‘Renal insufficiency”
may also have a great probability to have ‘‘Cardiac insufficiency”.
4.4. Treatment recommendation
To evaluate the performance of the proposed model, we pro-
pose one possible application, i.e., treatment recommendation, As
illustrated above, given a set of diagnosis labels cr of a particular
patient trace, the clinical activity probability PðajcrÞ represents
the most likely medications for r, which can be measured as
follows:
PðajcrÞ ¼
X
z2Z
PðajzÞPðzjcrÞ ¼
X
z2Z
X
c2cr
PðajzÞPðzjcÞ ¼
X
z2Z
X
c2cr
hc;z/z;a:
ð12Þ
Table 3
Treatment recommendations using both the proposed DTM and the Naïve Bayes
based model.
MP@10 MAP
DTM 0.887 0.576
Naïve Bayes based model 0.853 0.550
TPM 0.885 0.572
CPM 0.865 0.557
LDA 0.871 0.562
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tion that the diagnosis and treatments given by clinicians for par-
ticular patients are the ground-truth.1 Then we test the consistency
of the possible treatments suggested by our model with the ground
truth. To this end, we split the log into a training set and a testing set,
and evaluate the performance by 10-fold cross-validation. In partic-
ular, we recommended both the top 10 types of treatment activities
for each patient trace, and the same number of treatment activities
of each patient trace. Then, we checked if the recommended activi-
ties are actually included in the ground truth. In this sense, we utilize
two measurements, i.e., ‘‘mean precision at top 10” (MP@10Þ, and
‘‘mean average precision” (MAP).
We compare the results with both the Naïve Bayes based model,
the standard LDA, and the other two extensions of LDA proposed in
our previous work, i.e., CPM [24] and TPM [19]. Note that CPM does
not take the comorbidities into account during the generation of
latent treatment patterns from EMRs. With respect to TPM,
although it incorporates patient-specific information into the
model generation, it processes comorbidities as normal patient
variables and thus does not model the correlations between treat-
ments and comorbidities explicitly.
Table 3 shows MP@10 and MAP for the different models. The
LDA-based models outperform the baseline approach in terms of
treatment recommendation. Among the four LDA-based models,
the proposed DTM achieves the best performance although TPM
can obtain the comparative performance with DTM. The experi-
mental results indicate that the explicitly modeling of the correla-
tions between treatment behaviors and comorbidities can improve
the quality of treatment recommendations in CPs.5. Conclusions
In this paper, we explore a new problem called comorbidity-
incorporated latent treatment pattern mining from the execution
data of CPs, which aims to discover and model the associations
between comorbidities and treatment behaviors in CPs. In detail,
we propose a probabilistic statistical model to link clinician’s diag-
nosis labels and consequent treatment events together so as to
unveil the latent associations between diagnosis labels (including
both the first-diagnosis and comorbidities) and treatments, and
compute the contribution of comorbidities on treatments’ adop-
tion in CPs. The experimental results on a collection of 12,120
unstable angina patient traces from Chinese PLA General Hospital
reveal practical importance over the proposed approach for the
task of comorbidity-incorporated latent treatment pattern mining.
The discovered patterns can help clinicians better understand their
specialty and learn previous experiences from real healthcare data.
In particular, clinicians can utilize the discovered treatment pat-
terns to redesign composite clinical pathways with specific comor-
bidities into considerations.1 In clinical settings, the given diagnosis and treatments are biased. Even for the
same patient, different clinicians may have different opinions on patient conditions so
as to give different diagnosis and treatments.The model proposed in this paper offers many avenues for fur-
ther expansions and applications. In the future work, we aim to
study the merits of our proposal in further clinical collaborations
to investigate on additional sources of information (e.g., patient
features, medical resources, etc.), explore on the experiments
results, and empirical study the usage of our approach in real clin-
ical environments. As well, several extensions of our approach will
be investigated, such as treatment grouping and identification
within the same therapy and treatment intention and anomaly
detection for ongoing patient traces. These extensions will be
explored and evaluated on a larger scale of clinical data collections
as for our future work.Conflicts of interest
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